{"protocolSection": {"identificationModule": {"nctId": "NCT02821416", "orgStudyIdInfo": {"id": "D3250C00040"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics", "officialTitle": "A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics", "acronym": "ARIA"}, "statusModule": {"statusVerifiedDate": "2020-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-10-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-10-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-06-17", "studyFirstSubmitQcDate": "2016-06-29", "studyFirstPostDateStruct": {"date": "2016-07-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-10-22", "resultsFirstSubmitQcDate": "2020-12-14", "resultsFirstPostDateStruct": {"date": "2021-01-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-12-14", "lastUpdatePostDateStruct": {"date": "2021-01-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.", "detailedDescription": "This randomized, double-blind, parallel group, placebo-controlled study will evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks for 3 doses on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.\n\nApproximately 38 non-smoking men and women (18 - 65 years of age) corticosteroid-free (oral and inhaled) mild, atopic asthmatics who have demonstrated a dual (early and late) asthmatic response to inhaled allergen challenge at screening will be recruited to complete the study."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 46, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered subcutaneously", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive", "armGroupLabels": ["Benralizumab"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge", "description": "To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum", "timeFrame": "From prechallenge to 7 hours post allergen challenge during week 9"}, {"measure": "Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge", "description": "To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)", "timeFrame": "From prechallenge to 3 to 7 hours post allergen challenge during week 9"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female or male aged 18 to 65 years, inclusively, at the time of enrolment.\n3. General good health\n4. Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not more than twice weekly)\n5. Positive skin-prick test to at least one common aeroallergen\n\nExclusion Criteria:\n\n1. Current lung disease other than mild allergic asthma\n2. Any history or symptoms of disease, including, but not limited to, cardiovascular, neurologic, autoimmune or haematologic\n3. Any clinically significant abnormal findings in laboratory test results in complete blood count, coagulation, chemistry panel and urinalysis at enrolment and during screening period\n4. History of anaphylaxis to any biologic therapy or vaccine", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Edmonton", "state": "Alberta", "zip": "T6G 2B7", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7N 0W8", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "The CSP redacted.", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00040&amp;attachmentIdentifier=38fb2b0f-090e-4f1a-bfa3-f74c5941c69e&amp;fileName=d3250c00040-csp-4_-_Redacted_(1).pdf&amp;versionIdentifier="}, {"label": "The SAP redacted.", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00040&amp;attachmentIdentifier=d3ca7f3e-fb89-4822-97f4-85610a3f79cd&amp;fileName=d3250c00040-sap-v2_-_redacted.pdf&amp;versionIdentifier="}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Benra 30mg q.4 Week", "description": "Benralizumab 30mg every 4 Weeks"}, {"id": "FG001", "title": "Placebo", "description": "Placebo every 4 Weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benra 30mg q.4 Week", "description": "Benralizumab 30mg every 4 Weeks"}, {"id": "BG001", "title": "Placebo", "description": "Placebo every 4 Weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.4", "spread": "12.3"}, {"groupId": "BG001", "value": "31.5", "spread": "13.3"}, {"groupId": "BG002", "value": "30.9", "spread": "12.7"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": ">=18 - <=50", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}, {"title": ">50 - <=65", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": ">65 - <=75", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "34"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "35"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge", "description": "To evaluate the effect of benralizumab on allergen-induced increases in eosinophils in induced sputum", "populationDescription": "Primary Efficacy Analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "From prechallenge to 7 hours post allergen challenge during week 9", "groups": [{"id": "OG000", "title": "Benra 30mg q.4 Weeks", "description": "Benralizumab 30 mg every 4 Weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo every 4 Weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.822", "spread": "4.054"}, {"groupId": "OG001", "value": "6.468", "spread": "9.560"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0208", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes covariates of treatment, time post-allergen challenge , treatment\\*time post-allergen challenge, allergen induced at screening", "paramType": "Median Difference (Final Values)", "paramValue": "-5.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.69", "ciUpperLimit": "-0.94"}]}, {"type": "PRIMARY", "title": "Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge", "description": "To evaluate the effect of benralizumab on the allergen-induced late (3-7 hours post challenge) asthmatic response (LAR)", "populationDescription": "Primary Efficacy Analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "From prechallenge to 3 to 7 hours post allergen challenge during week 9", "groups": [{"id": "OG000", "title": "Benra 30mg q.4 Weeks", "description": "Benralizumab 30mg every 4 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo every 4 Weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.152", "spread": "8.834"}, {"groupId": "OG001", "value": "16.275", "spread": "10.235"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3630", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes covariates of treatment, maximum percent decrease in FEV1 late asthma response", "paramType": "Median Difference (Final Values)", "paramValue": "2.535", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.045", "ciUpperLimit": "8.116"}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "From Visit 1a to Visit 17", "eventGroups": [{"id": "EG000", "title": "Benra 30mg q.4 Week", "description": "Benralizumab 30mg every 4 Weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 7, "otherNumAtRisk": 23}, {"id": "EG001", "title": "Placebo", "description": "Placebo every 4 Weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 14, "otherNumAtRisk": 23}], "otherEvents": [{"term": "Cyanosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Catheter site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Vessel puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Biliary colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Nonalcoholic fatty liver disease", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 23}]}, {"term": "Gastrointestinal viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 23}]}, {"term": "Periodontitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Tooth infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Post procedural discomfort", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 23}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 23}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 23}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}]}, {"term": "Peripheral coldness", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This allergen challenge study was conducted in a mild, atopic asthma patient population, distinct from the current approved severe eosinophilic asthma indication."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Maria Jison", "organization": "AstraZeneca", "email": "Maria.Jison@astrazeneca.com", "phone": "001-202-577-6213"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-03-26", "uploadDate": "2020-10-22T14:57", "filename": "Prot_000.pdf", "size": 937362}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-10-22", "uploadDate": "2020-10-22T14:57", "filename": "SAP_001.pdf", "size": 434608}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000007249", "term": "Inflammation"}], "ancestors": [{"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M10293", "name": "Inflammation", "asFound": "Inflammation", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}